Novel combo therapy may benefit head, neck cancer patientsMay 31st, 2009 - 3:34 pm ICT by ANI
Washington, May 31 (ANI): A new study has found that patients undergoing treatment for advanced head and neck cancers may benefit from the addition of gefinitib to chemotherapy.
“We found that adding gefinitib to standard chemotherapy was well-tolerated by patients who had already received chemotherapy or were frail,” said Ethan Argiris, M.D., associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI).
“We had hoped this study would improve the survival rate of patients, but while gefinitib did postpone spread of the disease, it did not increase survival rates. The finding that the addition of gefinitib to chemotherapy can delay the growth of head and neck cancer suggests a potential beneficial effect from combination therapy,” Argiris added.
One group of 136 patients in the placebo-controlled study received docetaxel alone, a standard treatment for head and neck cancer. A second group of 134 patients received gefinitib in addition to docetaxel.
This was the first phase III randomized trial to examine the addition of gefinitib to chemotherapy for patients with head and neck cancer.
Gefinitib, which also is known by the trade name Iressa, is a targeted therapy against the epidermal growth factor receptor (EGFR) with fewer side effects than traditional chemotherapies. Patients were able to take the drug orally and tolerated it well.
Argiris is planning to conduct further studies to identify the subsets of patients most likely to respond to the drug and to examine patients’ quality of life while taking the combination therapy.
The results will be disclosed at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) on May 30 in Orlando, Fla. (ANI)
- Chemo-Vandetanib combo effective for lung cancer treatment: Study - Jun 06, 2010
- Combining radiation therapy, chemo safely treats head and neck cancers - Nov 04, 2010
- Combination treatment ineffective for advanced melanoma patients - Jun 06, 2010
- Targeted cancer drug more effective after first-line treatment - Feb 28, 2011
- FDA approves personalized therapy for tough-to-treat colorectal cancer - Jul 26, 2012
- New treatment strategy effective for certain lung cancers - Mar 11, 2011
- Indian-origin scientist's finding offers hope for advanced cancer patients - Apr 06, 2011
- Molecular switch that helps pancreatic cancer beat drugs identified - Jan 29, 2010
- How progesterone and estrogen increase breast cancer risk - Jan 19, 2011
- Most common adult brain cancer associated with gene deletion - Dec 23, 2010
- Osteoporosis drug may benefit patients with oral cancer - Dec 14, 2010
- Radiation therapy 'treats pain in patients with advanced cancer' - Nov 04, 2009
- Adopting 'synthetic lethality' could boost molecularly targeted cancer therapy - Sep 22, 2010
- 8 genes that help predict melanoma patient's response to treatment identified - May 31, 2009
- Chemo-radiation combo may avert prostate cancer recurrence - Nov 05, 2009
Tags: cancer program, combination therapy, docetaxel, egfr, epidermal growth factor, epidermal growth factor receptor, gefinitib, growth factor receptor, head and neck cancer, iressa, medicine university, neck cancer patients, neck cancers, pittsburgh cancer institute, pittsburgh school, randomized trial, survival rate, survival rates, undergoing treatment, university of pittsburgh school of medicine